

NCI-H322 | 305839

General Information

Description	NCI-H322 (NSCLC) is a cell line derived from a patient with non-small cell lung cancer. It is characterized by mutations in KRAS, MAPK/ERK, and PI3K/AKT pathways. It is maintained in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) and 10% insulin, transferrin, and selenium (ITS) solution. It is a highly proliferative cell line with a doubling time of approximately 48 hours. It is used for studying lung cancer biology and drug response.
Organism	Human
Tissue	Lung
Disease	Non-small cell lung cancer (NSCLC)
Synonyms	H322, H-322, H322T, NCI-H322T, NCIH322T, NCI-322, NCIH322

Characteristics

Age	52 years
Gender	Male
Ethnicity	White
Cell type	Epithelial
Growth properties	Adherent

References and Accession

Citation	NCI-H322 (Cytion 305839)
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_1556

NCI-H322 | 305839

Cell Line

Mutational profile TP53, p.Arg248Leu (c.743G>T), (PubMed=1311061, PubMed=1565469, PubMed=10536175, PubMed=20557307).

Media

Culture Medium RPMI 1640, w: 2.0 mM, w: 2.0 g/L NaHCO3 (Cytion 820700a)

Supplements 10% FBS

Dissociation Reagent

Doubling time 50

Freeze medium (FBS) + 10% DMSO

Thawing and Culturing Cells

- 1. ...
- 2. ...
- 3. ...
- 4. ...
- 5. ...
- 6. ...
- 7. ...
- 8. ...

Incubation Atmosphere 37°C, 5% CO2

